Cover Image
Market Research Report
Product code
1024229

Myasthenia Gravis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

Published: | GervanoRA Data Services LLP | 211 Pages | Delivery time: 3-5 business days

Price

Back to Top
Myasthenia Gravis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis
Published: August 11, 2021
GervanoRA Data Services LLP
Content info: 211 Pages
Delivery time: 3-5 business days
  • ALL
  • Description
  • Table of Contents
Description

GervanoRA's pipeline analysis and opportunity assessment report "Myasthenia Gravis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Myasthenia Gravis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Myasthenia Gravis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Myasthenia Gravis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Myasthenia Gravis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Myasthenia Gravis Market (2020) and the Forecasted Myasthenia Gravis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Myasthenia Gravis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Myasthenia Gravis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Myasthenia Gravis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

Table of Contents
Product Code: GERPH606

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: MYASTHENIA GRAVIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF MYASTHENIA GRAVIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF MYASTHENIA GRAVIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: SIGNS AND SYMPTOMS OF MG
  • TABLE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY (2020) AND FORECAST (2021-2030), IN MILLION
  • TABLE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY (2020) AND FORECAST (2021-2030), IN MILLION
  • TABLE 05: PHASE 3 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 06: PHASE 2 MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 07: PRECLINICAL MOLECULES IN MYASTHENIA GRAVIS DRUG PIPELINE
  • TABLE 08: TERMINATED DRUGS FOR MG
  • TABLE 09: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY INJECTABLE AS ROA
  • TABLE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY ORAL AS ROA
  • TABLE 11: DRUG CLASSES SCENARIO IN THE MG DRUG PIPELINE
  • TABLE 12: COMMON TARGETS IN THE MG DRUG PIPELINE
  • TABLE 13: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE
  • TABLE 14: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY UNIVERSITIES
  • TABLE 15: ESTIMATED APPROVAL TIMELINE OF KEY PIPELINE DRUGS FOR MYASTHENIA GRAVIS

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN MYASTHENIA GRAVIS DISEASE AREA
  • FIGURE 02: MYASTHENIA GRAVIS DISEASE CLASSIFICATION
  • FIGURE 03: MYASTHENIA GRAVIS WORLDWIDE EPIDEMIOLOGY FORECAST (2021-2030)
  • FIGURE 04: MYASTHENIA GRAVIS US EPIDEMIOLOGY FORECAST (2021-2030)
  • FIGURE 05: MYASTHENIA GRAVIS DEALS SCENARIO
  • FIGURE 06: MYASTHENIA GRAVIS PIPELINE DRUGS WITH RESPECT TO STAGES OF DEVELOPMENT
  • FIGURE 07: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY GEOGRAPHY
  • FIGURE 08: MYASTHENIA GRAVIS DRUG PIPELINE SPLIT BY ROA
  • FIGURE 09: SPLIT UP BY HSD WITH RESPECT TO INJECTABLE ROUTE
  • FIGURE 10: MYASTHENIA GRAVIS PIPELINE ANALYTICS BY COMPANY TYPE